Filing Details

Accession Number:
0002050709-25-000003
Form Type:
13G Filing
Publication Date:
2025-04-30 20:00:00
Filed By:
Squadron Master Fund LP
Company:
Relmada Therapeutics Inc. (NASDAQ:RLMD)
Filing Date:
2025-05-01
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Squadron Master Fund LP 0 1,821,835 5.5%
Squadron Capital Management LLC 0 2,050,000 6.2%
William Blank 0 2,050,000 6.2%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
Squadron Master Fund LP
 
Signature:/s/ Matt Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:05/01/2025
 
Squadron Capital Management LLC
 
Signature:/s/ Matt Sesterhenn
Name/Title:Partner
Date:05/01/2025
 
William Blank
 
Signature:/s/ William Blank
Name/Title:William Blank
Date:05/01/2025